TNFRSF4 and neoplasm: Antitumor effects of combined anti-PD-1 mAb and anti-OX40 mAb in a murine ovarian cancer model increased the activity of effector CD4+ and CD8+ T cells and attenuated the action of immunosuppressive CD4+FoxP3+ regulatory T cells in tumor sites [20].